Clinical data
Trade names Restas
AHFS/Drugs.com International Drug Names
  • US: X (Contraindicated)
Routes of
Oral, Intravenous
ATC code none
Legal status
Legal status
Pharmacokinetic data
Bioavailability 80-90%
Metabolism Hepatic
Biological half-life 60-90 hours
Excretion Renal
CAS Number 25967-29-7 YesY
PubChem (CID) 3400
ChemSpider 3283 YesY
KEGG D01279 YesY
Chemical and physical data
Formula C19H16ClFN2O
Molar mass 342.795
3D model (Jmol) Interactive image

Flutoprazepam (Restas) is a drug which is a benzodiazepine. It was patented in Japan by Sumitomo in 1972[1] and its medical use remains mostly confined to that country. Its muscle relaxant properties are approximately equivalent to those of diazepam - however, it has more powerful sedative, hypnotic, anxiolytic and anticonvulsant effects and is around four times more potent by weight compared to diazepam.[2] It is longer acting than diazepam due to its long-acting active metabolites,[3] which contribute significantly to its effects.[4]

Flutoprazepam is typically used for the treatment of severe insomnia and may also be used for treating stomach ulcers.[5]

Flutoprazepam is currently a Schedule IV drug under the international Convention on Psychotropic Substances of 1971.[6][7]

See also


  1. US patent 3632574, Hisao Yamamoto et al, "PROCESS FOR PRODUCING BENZODIAZEPINE DERIVATIVES", published 1968-29-04, issued 1972-04-01
  2. Sukamoto, T.; Aikawa, K.; Itoh, K.; Nose, T. (Sep 1980). "[Psycopharmacological and general pharmacological studies of 7-chloro-1-cyclopropylmethyl-1, 3-dihydro-5-(2-fluorophenyl)-2H-1, 4-benzodiazepin-2-one (KB-509) (author's transl)]". Nippon Yakurigaku Zasshi. 76 (6): 447–68. doi:10.1254/fpj.76.447. PMID 7203280.
  3. Ueki, S.; Sukamoto, T.; Watanabe, S.; Yamamoto, T.; Kataoka, Y.; Shibata, S.; Suwandi, D.; Shibata, K.; et al. (Jul 1982). "[Behavioral effects of flutoprazepam (KB-509) and its metabolites]". Nippon Yakurigaku Zasshi. 80 (1): 15–30. doi:10.1254/fpj.80.15. PMID 6890927.
  4. Barzaghi, N.; Leone, L.; Monteleone, M.; Tomasini, G.; Perucca, E. (1989). "Pharmacokinetics of flutoprazepam, a novel benzodiazepine drug, in normal subjects.". Eur J Drug Metab Pharmacokinet. 14 (4): 293–8. doi:10.1007/BF03190114. PMID 2633923.
  5. Fukuda, T.; Itoh, K.; Nose, T. (Mar 1981). "[Antiulcerogenic action of 7-chloro-1-cyclopropylmethyl-1,3-dihydro-5-(2-fluorophenyl)-2H-1,4-benzodiazepin-2-one (KB-509), a new benzodiazepine derivative]". Nippon Yakurigaku Zasshi. 77 (3): 273–80. doi:10.1254/fpj.77.273. PMID 7052359.
  6. http://www.cnb.gov.sg/ [Central Narcotics Bureau, Singapore]
  7. "Green List—List of psychotropic substances under international control" (PDF) (23rd ed.). International Narcotics Control Board. August 2003. Retrieved 2007-11-25.
  8. "Bilingual Laws Information System" (English). The Government of the Hong Kong Special Administrative Region of the People's Republic of China.
This article is issued from Wikipedia - version of the 8/24/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.